



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

November 2014





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.682.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

November 2014

N = 6763



Health Authority	Male	Female	All
FRASER	1210	359	1569
INTERIOR	317	94	411
NORTHERN	122	84	206
VANCOUVER COASTAL	3269	448	3717
VANCOUVER ISLAND	609	140	749
	<b>5527</b>	<b>1125</b>	<b>6652</b>
		<b>Unknown/not stated:</b>	<b>111</b>
		<b>Total:</b>	<b>6763</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2009 - November 2014)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2009 - November 2014)








### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (November 2009 - November 2014)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (November 2009 - November 2014)






### 1.6 Percent Distribution of Active Participants by CD4 Count (November 2009 - November 2014)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(November 2009 - November 2014)





### 1.8 Active and Inactive Participants (November 2009 - November 2014)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (November 2009 - November 2014)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (November 2009 - November 2014)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(November 2009 - November 2014)








1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT  
(November 2009 - November 2014)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(November 2009 - November 2014)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (November 2009 - November 2014)






### 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(November 2009 - November 2014)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (November 2009 - November 2014)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(November 2009 - November 2014)






1.18 Baseline CD4 for Antiretroviral First Starts  
(November 2009 - November 2014)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(November 2009 - November 2014)**








### 1.20 Cumulative Resistance Testing Results by Resistance Category (November 2009 - November 2014)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category  
(November 2009 - November 2014)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2014  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	680	5	<40	4
1988	23	7	0	7	7	410	7	<40	4
1989	21	59	2	61	55	520	60	<40	4
1990	20	62	1	63	58	535	62	<40	4
1991	20	38	3	41	35	610	40	<40	4
1992	20	69	6	75	61	540	75	<40	4
1993	19	146	16	162	147	550	160	<40	4
1994	18	98	13	111	91	580	109	<40	4
1995	18	125	25	150	123	560	145	<40	4
1996	16	389	66	455	386	550	436	<40	4
1997	14	313	39	352	312	590	338	<40	3
1998	13	224	51	275	227	550	260	<40	4
1999	13	189	42	231	191	540	222	<40	3
2000	14	145	37	182	149	580	167	<40	3
2001	13	138	41	179	147	530	177	<40	3
2002	12	144	31	175	144	535	166	<40	3
2003	11	180	33	213	183	590	207	<40	3
2004	10	186	47	233	202	540	225	<40	3
2005	9	215	53	268	227	550	257	<40	4
2006	8	223	50	273	219	540	259	<40	3
2007	7	291	58	349	287	560	337	<40	3
2008	6	328	79	407	339	590	385	<40	3
2009	5	352	76	428	358	630	410	<40	3
2010	4	329	80	409	341	610	394	<40	3
2011	3	382	85	467	391	620	452	<40	3
2012	2	328	71	399	338	629	387	<40	3
2013	1	321	79	400	335	600	391	<40	3
2014	1	321	59	380	339	580	369	<40	4
<b>Total:</b>		<b>5607</b>	<b>1143</b>	<b>6750</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2013	6296	746	2410	<40	2174	520
FEB-2013	6298	751	1949	<40	1702	530
MAR-2013	6280	759	1901	<40	1709	510
APR-2013	6345	763	2182	<40	1938	530
MAY-2013	6364	753	2149	<40	1901	530
JUN-2013	6387	754	1944	<40	1726	536
JUL-2013	6430	756	2148	<40	1923	520
AUG-2013	6434	769	1994	<40	1734	530
SEP-2013	6439	777	2054	<40	1836	550
OCT-2013	6457	781	2195	<40	1945	530
NOV-2013	6504	781	1926	<40	1704	540
DEC-2013	6525	785	1800	<40	1586	560
JAN-2014	6557	785	2427	<40	2144	560
FEB-2014	6570	785	1895	<40	1654	550
MAR-2014	6599	788	2154	<40	1927	550
APR-2014	6613	790	2124	<40	1867	560
MAY-2014	6679	769	2118	<40	1882	560
JUN-2014	6648	784	1994	<40	1761	550
JUL-2014	6686	780	2178	<40	1913	550
AUG-2014	6706	775	2026	<40	1779	570
SEP-2014	6739	770	2284	<40	1947	550
OCT-2014	6771	761	2251	<40	1863	580
NOV-2014	6763	759	1921	<40	1317	590

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2013	1388	2222	111	3811	85	380
FEB-2013	1408	2139	95	5364	81	361
MAR-2013	1442	2002	93	1216	75	340
APR-2013	1398	2181	107	2091	86	345
MAY-2013	1408	2138	88	1857	73	390
JUN-2013	1390	2281	73	1205	66	410
JUL-2013	1388	2292	88	17614	81	300
AUG-2013	1414	2168	85	375	78	440
SEP-2013	1434	2138	92	1832	72	355
OCT-2013	1431	2173	105	542	92	400
NOV-2013	1414	2246	93	240	86	350
DEC-2013	1419	2247	71	1296	49	400
JAN-2014	1418	2266	100	6683	76	285
FEB-2014	1439	2213	73	496	67	490
MAR-2014	1440	2181	115	3890	97	340
APR-2014	1449	2163	112	128	90	400
MAY-2014	1420	2338	90	617	75	340
JUN-2014	1473	2079	96	423	81	380
JUL-2014	1465	2124	95	982	74	355
AUG-2014	1459	2183	88	249	73	370
SEP-2014	1453	2219	103	1031	89	400
OCT-2014	1440	2324	84	257	60	395
NOV-2014	1461	2241	72	3945	44	435

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2013	6270	1388	13	38	141	127	37	11044
FEB-2013	6278	1408	2	32	110	128	8	11080
MAR-2013	6252	1442	13	27	121	159	-26	11108
APR-2013	6321	1398	6	28	186	138	70	11141
MAY-2013	6339	1408	9	39	136	145	18	11186
JUN-2013	6372	1390	6	24	138	122	33	11213
JUL-2013	6407	1388	10	42	130	121	35	11265
AUG-2013	6408	1414	8	37	114	139	1	11307
SEP-2013	6411	1434	11	35	125	143	3	11347
OCT-2013	6431	1431	8	24	156	148	20	11378
NOV-2013	6479	1414	7	23	172	138	48	11418
DEC-2013	6504	1419	6	28	154	148	25	11458
JAN-2014	6539	1418	2	30	144	136	35	11501
FEB-2014	6548	1439	9	40	139	159	9	11545
MAR-2014	6574	1440	9	36	152	146	26	11589
APR-2014	6589	1449	5	27	159	160	15	11625
MAY-2014	6648	1420	14	38	190	151	59	11675
JUN-2014	6623	1473	7	26	142	183	-25	11715
JUL-2014	6665	1465	8	34	176	159	42	11759
AUG-2014	6690	1459	6	19	165	151	25	11792
SEP-2014	6728	1453	2	25	171	156	38	11831
OCT-2014	6756	1440	7	22	161	147	28	11859
NOV-2014	6750	1461	8	20	133	151	-6	11883

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2013	52	5754	404	86	<b>6296</b>	0.83%	91.39%	6.42%	1.37%	<b>100.00%</b>
FEB-2013	51	5756	404	87	<b>6298</b>	0.81%	91.39%	6.41%	1.38%	<b>100.00%</b>
MAR-2013	52	5745	403	80	<b>6280</b>	0.83%	91.48%	6.42%	1.27%	<b>100.00%</b>
APR-2013	56	5801	410	78	<b>6345</b>	0.88%	91.43%	6.46%	1.23%	<b>100.00%</b>
MAY-2013	54	5820	415	75	<b>6364</b>	0.85%	91.45%	6.52%	1.18%	<b>100.00%</b>
JUN-2013	57	5844	408	78	<b>6387</b>	0.89%	91.50%	6.39%	1.22%	<b>100.00%</b>
JUL-2013	54	5881	420	75	<b>6430</b>	0.84%	91.46%	6.53%	1.17%	<b>100.00%</b>
AUG-2013	53	5892	420	69	<b>6434</b>	0.82%	91.58%	6.53%	1.07%	<b>100.00%</b>
SEP-2013	50	5904	415	70	<b>6439</b>	0.78%	91.69%	6.45%	1.09%	<b>100.00%</b>
OCT-2013	46	5927	420	64	<b>6457</b>	0.71%	91.79%	6.50%	0.99%	<b>100.00%</b>
NOV-2013	47	5977	412	68	<b>6504</b>	0.72%	91.90%	6.33%	1.05%	<b>100.00%</b>
DEC-2013	48	6000	410	67	<b>6525</b>	0.74%	91.95%	6.28%	1.03%	<b>100.00%</b>
JAN-2014	47	6025	414	71	<b>6557</b>	0.72%	91.89%	6.31%	1.08%	<b>100.00%</b>
FEB-2014	50	6034	418	68	<b>6570</b>	0.76%	91.84%	6.36%	1.04%	<b>100.00%</b>
MAR-2014	50	6055	424	70	<b>6599</b>	0.76%	91.76%	6.43%	1.06%	<b>100.00%</b>
APR-2014	46	6069	422	76	<b>6613</b>	0.70%	91.77%	6.38%	1.15%	<b>100.00%</b>
MAY-2014	46	6141	418	74	<b>6679</b>	0.69%	91.94%	6.26%	1.11%	<b>100.00%</b>
JUN-2014	46	6114	417	71	<b>6648</b>	0.69%	91.97%	6.27%	1.07%	<b>100.00%</b>
JUL-2014	45	6152	416	73	<b>6686</b>	0.67%	92.01%	6.22%	1.09%	<b>100.00%</b>
AUG-2014	45	6175	414	72	<b>6706</b>	0.67%	92.08%	6.17%	1.07%	<b>100.00%</b>
SEP-2014	48	6194	426	71	<b>6739</b>	0.71%	91.91%	6.32%	1.05%	<b>100.00%</b>
OCT-2014	44	6218	436	73	<b>6771</b>	0.65%	91.83%	6.44%	1.08%	<b>100.00%</b>
NOV-2014	45	6224	424	70	<b>6763</b>	0.67%	92.03%	6.27%	1.04%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2013	9 20%	2292 37%	9 20%	1870 31%	0 0%	160 3%	0 0%	31 1%	0 0%	29 0%	36 80%	3686 60%	36 80%	4146 68%
FEB-2013	5 14%	2299 38%	3 8%	1877 31%	2 6%	159 3%	0 0%	31 1%	0 0%	28 0%	31 86%	3680 60%	31 86%	4138 68%
MAR-2013	4 14%	2288 38%	3 11%	1871 31%	0 0%	156 3%	0 0%	30 0%	0 0%	28 0%	24 86%	3673 60%	25 89%	4121 68%
APR-2013	3 9%	2307 37%	2 6%	1897 31%	0 0%	154 3%	0 0%	29 0%	0 0%	23 0%	30 91%	3717 60%	30 91%	4156 67%
MAY-2013	6 13%	2310 37%	6 13%	1897 31%	0 0%	151 2%	0 0%	30 0%	0 0%	23 0%	39 87%	3744 61%	39 87%	4175 68%
JUN-2013	2 8%	2300 37%	1 4%	1890 31%	0 0%	147 2%	0 0%	29 0%	0 0%	23 0%	24 92%	3761 61%	24 92%	4197 68%
JUL-2013	12 23%	2331 37%	8 15%	1921 31%	3 6%	150 2%	0 0%	31 0%	0 0%	22 0%	40 77%	3787 61%	40 77%	4217 68%
AUG-2013	7 17%	2325 37%	6 14%	1925 31%	1 2%	151 2%	0 0%	29 0%	0 0%	21 0%	35 83%	3776 61%	35 83%	4201 67%
SEP-2013	5 13%	2329 37%	5 13%	1931 31%	1 3%	145 2%	0 0%	28 0%	0 0%	18 0%	35 88%	3791 61%	35 88%	4211 67%
OCT-2013	3 10%	2347 37%	2 6%	1952 31%	0 0%	143 2%	0 0%	26 0%	0 0%	17 0%	28 90%	3792 61%	29 94%	4205 67%
NOV-2013	7 18%	2348 37%	5 13%	1957 31%	1 3%	143 2%	0 0%	24 0%	0 0%	16 0%	32 82%	3836 61%	33 85%	4251 67%
DEC-2013	9 23%	2353 37%	8 21%	1968 31%	1 3%	138 2%	0 0%	26 0%	0 0%	17 0%	30 77%	3849 61%	30 77%	4257 67%
JAN-2014	8 19%	2382 37%	7 17%	1995 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3864 61%	36 86%	4271 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3881 61%	37 84%	4287 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3894 61%	38 86%	4299 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3906 61%	33 92%	4303 67%
MAY-2014	17 34%	2435 38%	16 32%	2059 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3931 61%	33 66%	4327 67%
JUN-2014	8 20%	2432 38%	9 23%	2064 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	31 78%	3911 61%	31 78%	4299 67%
JUL-2014	13 30%	2464 38%	11 25%	2096 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3922 60%	32 73%	4302 66%
AUG-2014	7 22%	2475 38%	7 22%	2109 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	25 78%	3915 60%	25 78%	4289 66%
SEP-2014	15 38%	2520 39%	12 31%	2149 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3912 60%	24 62%	4292 66%
OCT-2014	11 39%	2548 39%	10 36%	2175 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 61%	3915 60%	17 61%	4296 65%
NOV-2014	6 25%	2548 39%	6 25%	2182 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3901 59%	19 79%	4274 65%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2013	0 0%	34 1%	17 85%	2363 66%	2 10%	599 17%	1 5%	570 16%	0 0%	9 0%	0 0%	3 0%	0 0%	38 1%
FEB-2013	1 6%	30 1%	12 67%	2355 66%	4 22%	615 17%	1 6%	556 16%	0 0%	9 0%	0 0%	3 0%	0 0%	38 1%
MAR-2013	0 0%	29 1%	12 100%	2338 66%	0 0%	609 17%	0 0%	542 15%	0 0%	10 0%	0 0%	4 0%	0 0%	36 1%
APR-2013	0 0%	26 1%	9 82%	2332 66%	2 18%	630 18%	0 0%	547 15%	0 0%	10 0%	0 0%	3 0%	0 0%	35 1%
MAY-2013	0 0%	26 1%	10 56%	2339 65%	6 33%	647 18%	2 11%	537 15%	0 0%	9 0%	0 0%	3 0%	0 0%	36 1%
JUN-2013	0 0%	25 1%	4 44%	2340 65%	4 44%	654 18%	1 11%	525 15%	0 0%	8 0%	0 0%	3 0%	0 0%	35 1%
JUL-2013	0 0%	26 1%	17 71%	2355 66%	7 29%	682 19%	0 0%	517 14%	0 0%	8 0%	0 0%	4 0%	0 0%	34 1%
AUG-2013	0 0%	24 1%	17 77%	2342 65%	4 18%	688 19%	1 5%	510 14%	0 0%	8 0%	0 0%	3 0%	0 0%	33 1%
SEP-2013	1 5%	22 1%	11 55%	2307 65%	7 35%	702 20%	1 5%	501 14%	0 0%	9 0%	0 0%	3 0%	0 0%	32 1%
OCT-2013	0 0%	21 1%	8 62%	2301 65%	4 31%	709 20%	1 8%	496 14%	0 0%	9 0%	0 0%	2 0%	0 0%	31 1%
NOV-2013	0 0%	20 1%	8 67%	2307 65%	3 25%	735 21%	1 8%	488 14%	0 0%	7 0%	0 0%	3 0%	0 0%	29 1%
DEC-2013	0 0%	18 1%	13 72%	2301 65%	4 22%	735 21%	1 6%	476 13%	0 0%	8 0%	0 0%	3 0%	0 0%	29 1%
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	740 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	762 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2260 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2251 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	2 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	6 35%	2201 63%	9 53%	831 24%	2 12%	449 13%	0 0%	5 0%	0 0%	2 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2186 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2156 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2143 62%	6 46%	869 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2138 62%	5 50%	891 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2109 62%	2 17%	895 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

**2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)**

	Tipranavir			
	Initial		All	
JAN-2013	0	0%	1	0%
FEB-2013	0	0%	1	0%
MAR-2013	0	0%	1	0%
APR-2013	0	0%	1	0%
MAY-2013	0	0%	1	0%
JUN-2013	0	0%	1	0%
JUL-2013	0	0%	1	0%
AUG-2013	0	0%	1	0%
SEP-2013	0	0%	0	0%
OCT-2013	0	0%	0	0%
NOV-2013	0	0%	1	0%
DEC-2013	0	0%	1	0%
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	Delavirdine		Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2013	0 0%	1 0%	13 65%	1406 51%	1 5%	273 10%	1 5%	958 35%	5 25%	130 5%
FEB-2013	0 0%	1 0%	13 81%	1409 51%	0 0%	276 10%	1 6%	967 35%	2 13%	144 5%
MAR-2013	0 0%	1 0%	9 75%	1389 50%	0 0%	274 10%	0 0%	957 35%	3 25%	162 6%
APR-2013	0 0%	1 0%	12 60%	1389 50%	0 0%	282 10%	2 10%	960 34%	6 30%	177 6%
MAY-2013	0 0%	1 0%	14 67%	1375 49%	1 5%	291 10%	0 0%	955 34%	6 29%	189 7%
JUN-2013	0 0%	1 0%	8 73%	1381 49%	1 9%	291 10%	0 0%	944 34%	2 18%	187 7%
JUL-2013	0 0%	0 0%	9 47%	1374 49%	1 5%	300 11%	5 26%	951 34%	4 21%	193 7%
AUG-2013	0 0%	0 0%	12 92%	1350 48%	0 0%	301 11%	0 0%	953 34%	1 8%	192 7%
SEP-2013	0 0%	0 0%	12 80%	1357 48%	0 0%	306 11%	1 7%	956 34%	2 13%	195 7%
OCT-2013	0 0%	0 0%	13 87%	1350 48%	0 0%	299 11%	0 0%	957 34%	2 13%	201 7%
NOV-2013	0 0%	0 0%	13 65%	1344 48%	0 0%	307 11%	2 10%	953 34%	5 25%	213 8%
DEC-2013	0 0%	0 0%	8 50%	1353 48%	0 0%	305 11%	2 13%	946 34%	6 38%	226 8%
JAN-2014	0 0%	0 0%	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	0 0%	0 0%	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	0 0%	0 0%	10 71%	1321 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	0 0%	0 0%	4 57%	1305 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	0 0%	0 0%	5 71%	1299 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	0 0%	0 0%	4 44%	1281 46%	1 11%	303 11%	1 11%	926 33%	3 33%	259 9%
JUL-2014	0 0%	0 0%	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	258 9%
AUG-2014	0 0%	0 0%	12 86%	1261 46%	1 7%	304 11%	0 0%	928 34%	1 7%	254 9%
SEP-2014	0 0%	0 0%	8 73%	1256 46%	0 0%	300 11%	2 18%	929 34%	1 9%	251 9%
OCT-2014	0 0%	0 0%	3 60%	1233 45%	2 40%	306 11%	0 0%	922 34%	0 0%	255 9%
NOV-2014	0 0%	0 0%	2 100%	1208 45%	0 0%	303 11%	0 0%	910 34%	0 0%	252 9%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2013	0 0%	2 0%	0 0%	1 0%	0 0%	67 8%	6 100%	818 95%	0 0%	1 0%
FEB-2013	0 0%	2 0%	0 0%	1 0%	1 50%	70 8%	1 50%	822 95%	0 0%	1 0%
MAR-2013	0 0%	2 0%	0 0%	1 0%	1 25%	72 8%	3 75%	831 94%	0 0%	1 0%
APR-2013	0 0%	2 0%	0 0%	1 0%	0 0%	72 8%	3 100%	858 94%	0 0%	1 0%
MAY-2013	0 0%	2 0%	3 43%	9 1%	0 0%	73 8%	4 57%	871 94%	0 0%	1 0%
JUN-2013	0 0%	2 0%	5 56%	25 3%	0 0%	76 8%	4 44%	892 92%	0 0%	1 0%
JUL-2013	0 0%	3 0%	6 55%	53 5%	1 9%	79 8%	4 36%	897 90%	0 0%	1 0%
AUG-2013	0 0%	3 0%	3 50%	73 7%	0 0%	77 8%	3 50%	901 88%	0 0%	2 0%
SEP-2013	0 0%	3 0%	4 80%	93 9%	0 0%	74 7%	1 20%	920 87%	0 0%	2 0%
OCT-2013	0 0%	4 0%	3 100%	105 10%	0 0%	78 7%	0 0%	913 85%	0 0%	3 0%
NOV-2013	0 0%	5 0%	3 38%	116 11%	1 13%	80 7%	4 50%	924 84%	0 0%	3 0%
DEC-2013	0 0%	6 1%	4 67%	131 12%	0 0%	78 7%	2 33%	922 83%	0 0%	3 0%
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	77 6%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	254 18%	0 0%	75 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	75 5%	2 18%	920 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	282 18%	0 0%	74 5%	4 27%	921 58%	0 0%	1 0%
OCT-2014	8 50%	407 25%	6 38%	310 19%	0 0%	71 4%	2 13%	908 55%	0 0%	1 0%
NOV-2014	5 45%	453 27%	5 45%	325 19%	0 0%	70 4%	1 9%	895 53%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2013	2581	40.99	2256	35.83	347	5.51	196	3.11	86	1.37	830	13.18
FEB-2013	2566	40.74	2268	36.01	350	5.56	194	3.08	87	1.38	833	13.23
MAR-2013	2547	40.56	2265	36.07	365	5.81	194	3.09	80	1.27	829	13.20
APR-2013	2567	40.46	2292	36.12	374	5.89	186	2.93	78	1.23	848	13.36
MAY-2013	2578	40.51	2290	35.98	383	6.02	186	2.92	75	1.18	852	13.39
JUN-2013	2574	40.30	2290	35.85	407	6.37	190	2.97	78	1.22	848	13.28
JUL-2013	2587	40.23	2288	35.58	432	6.72	186	2.89	75	1.17	862	13.41
AUG-2013	2587	40.21	2280	35.44	448	6.96	186	2.89	69	1.07	864	13.43
SEP-2013	2554	39.66	2284	35.47	483	7.50	184	2.86	70	1.09	864	13.42
OCT-2013	2558	39.62	2288	35.43	493	7.64	189	2.93	64	0.99	865	13.40
NOV-2013	2574	39.58	2303	35.41	510	7.84	188	2.89	68	1.05	861	13.24
DEC-2013	2579	39.52	2318	35.52	522	8.00	189	2.90	67	1.03	850	13.03
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.79	2311	35.02	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2543	38.45	2289	34.61	653	9.87	192	2.90	76	1.15	860	13.00
MAY-2014	2539	38.01	2276	34.08	739	11.06	193	2.89	74	1.11	858	12.85
JUN-2014	2506	37.70	2248	33.81	782	11.76	183	2.75	71	1.07	858	12.91
JUL-2014	2496	37.33	2236	33.44	840	12.56	191	2.86	73	1.09	850	12.71
AUG-2014	2467	36.79	2233	33.30	891	13.29	186	2.77	72	1.07	857	12.78
SEP-2014	2442	36.24	2224	33.00	947	14.05	187	2.77	71	1.05	868	12.88
OCT-2014	2423	35.78	2193	32.39	1011	14.93	192	2.84	73	1.08	879	12.98
NOV-2014	2425	35.86	2160	31.94	1058	15.64	184	2.72	70	1.04	866	12.80

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2013	38	3	2	9	12	12	420
FEB-2013	32	6	5	8	8	5	305
MAR-2013	27	4	3	6	8	6	380
APR-2013	28	4	2	8	3	10	320
MAY-2013	39	6	4	10	9	10	340
JUN-2013	24	4	1	0	6	13	550
JUL-2013	42	10	6	9	6	11	243
AUG-2013	37	7	4	11	8	6	295
SEP-2013	35	3	4	10	6	12	380
OCT-2013	24	1	4	5	11	3	399
NOV-2013	23	1	2	7	7	6	380
DEC-2013	28	0	3	4	5	15	510
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	26	3	1	6	7	8	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	19	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	22	1	4	7	4	5	300
NOV-2014	20	4	1	1	4	8	475

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2013	9565	2403
FEB-2013	9610	2422
MAR-2013	9623	2428
APR-2013	9676	2464
MAY-2013	9723	2480
JUN-2013	9753	2497
JUL-2013	9813	2524
AUG-2013	9844	2530
SEP-2013	9879	2542
OCT-2013	9926	2570
NOV-2013	9949	2566
DEC-2013	9974	2564
JAN-2014	10029	2581
FEB-2014	10053	2575
MAR-2014	10066	2561
APR-2014	10096	2564
MAY-2014	10120	2558
JUN-2014	10155	2566
JUL-2014	10167	2554
AUG-2014	10216	2588
SEP-2014	10258	2598
OCT-2014	10281	2606
NOV-2014	10316	2628

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
November 2014

N = 6763

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY









3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2014

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2014

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2014

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2014

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2014

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	11	13	7
	50+	18	28	13
	<b>Total HSDA:</b>	<b>29</b>	<b>41</b>	<b>20</b>
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	4	4	2
	35-49	19	25	13
	50+	42	55	34
	<b>Total HSDA:</b>	<b>66</b>	<b>85</b>	<b>50</b>
OKANAGAN	0-19	3	3	1
	20-34	15	16	11
	35-49	98	114	72
	50+	171	249	136
	<b>Total HSDA:</b>	<b>287</b>	<b>382</b>	<b>220</b>
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	13	13	10
	35-49	58	74	44
	50+	83	118	66
	<b>Total HSDA:</b>	<b>160</b>	<b>211</b>	<b>121</b>
<b>Total HA:</b>		<b>542</b>	<b>719</b>	<b>411</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	3
	20-34	32	33	23
	35-49	186	226	136
	50+	314	450	249
<b>Total HA:</b>		<b>542</b>	<b>719</b>	<b>411</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	414	564	317
Female	128	155	94

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	411	52	520	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	5	3
	<5 years	8	7
	<b>Total HSDA:</b>	<b>29</b>	<b>20</b>
KOOTENAY BOUNDARY	10 years or more	32	23
	5 years or more	16	13
	<5 years	18	14
	<b>Total HSDA:</b>	<b>66</b>	<b>50</b>
OKANAGAN	10 years or more	151	109
	5 years or more	74	57
	<5 years	62	54
	<b>Total HSDA:</b>	<b>287</b>	<b>220</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	81	54
	5 years or more	37	31
	<5 years	42	36
	<b>Total HSDA:</b>	<b>160</b>	<b>121</b>
<b>Total HA:</b>		<b>542</b>	<b>411</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	280	196
	5 years or more	132	104
	<5 years	130	111
<b>Total HA:</b>		<b>542</b>	<b>411</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	33	45	13	18
KOOTENAY BOUNDARY	58	104	26	42
OKANAGAN	185	617	72	219
THOMPSON/CARIBOO/SHUSWAP	119	387	43	98
<b>Total:</b>	<b>395</b>	<b>1153</b>	<b>154</b>	<b>377</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	3
KOOTENAY BOUNDARY	12
OKANAGAN	45
THOMPSON/CARIBOO/SHUSWAP	36
<b>Total:</b>	<b>96</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	20	21	12
	35-49	123	135	95
	50+	138	194	115
	<b>Total HSDA:</b>	<b>288</b>	<b>357</b>	<b>228</b>
FRASER NORTH	0-19	22	22	7
	20-34	95	96	80
	35-49	365	419	275
	50+	413	646	340
	<b>Total HSDA:</b>	<b>895</b>	<b>1183</b>	<b>702</b>
FRASER SOUTH	0-19	14	14	7
	20-34	82	83	62
	35-49	346	396	284
	50+	349	532	286
	Unknown	0	1	0
	<b>Total HSDA:</b>	<b>791</b>	<b>1026</b>	<b>639</b>
<b>Total HA:</b>		<b>1974</b>	<b>2566</b>	<b>1569</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	43	43	20
	20-34	197	200	154
	35-49	834	950	654
	50+	900	1372	741
	Unknown	0	1	0
<b>Total HA:</b>		<b>1974</b>	<b>2566</b>	<b>1569</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1484	1965	1210
Female	490	601	359

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1569	49	580	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	132	100
	5 years or more	83	67
	<5 years	73	61
	<b>Total HSDA:</b>	<b>288</b>	<b>228</b>
FRASER NORTH	10 years or more	419	307
	5 years or more	222	174
	<5 years	254	221
	<b>Total HSDA:</b>	<b>895</b>	<b>702</b>
FRASER SOUTH	10 years or more	357	272
	5 years or more	214	184
	<5 years	220	183
	<b>Total HSDA:</b>	<b>791</b>	<b>639</b>
<b>Total HA:</b>		<b>1974</b>	<b>1569</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	908	679
	5 years or more	519	425
	<5 years	547	465
<b>Total HA:</b>		<b>1974</b>	<b>1569</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	120	362	41	72
FRASER NORTH	223	1302	65	253
FRASER SOUTH	196	1109	50	339
<b>Total:</b>	<b>539</b>	<b>2773</b>	<b>156</b>	<b>664</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	169
FRASER NORTH	606
FRASER SOUTH	427
<b>Total:</b>	<b>1202</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	17	17	14
	35-49	88	102	74
	50+	182	300	160
	<b>Total HSDA:</b>	<b>289</b>	<b>421</b>	<b>248</b>
RICHMOND	0-19	8	8	2
	20-34	17	17	16
	35-49	52	55	42
	50+	63	101	50
	<b>Total HSDA:</b>	<b>140</b>	<b>181</b>	<b>110</b>
VANCOUVER	0-19	60	63	8
	20-34	392	401	308
	35-49	1683	2006	1296
	50+	2193	3648	1747
	<b>Total HSDA:</b>	<b>4328</b>	<b>6118</b>	<b>3359</b>
<b>Total HA:</b>		<b>4757</b>	<b>6720</b>	<b>3717</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	70	73	10
	20-34	426	435	338
	35-49	1823	2163	1412
	50+	2438	4049	1957
<b>Total HA:</b>		<b>4757</b>	<b>6720</b>	<b>3717</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4165	5894	3269
Female	590	824	448

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3717	50	590	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	163	135
	5 years or more	44	40
	<5 years	82	73
	<b>Total HSDA:</b>	<b>289</b>	<b>248</b>
RICHMOND	10 years or more	61	43
	5 years or more	33	23
	<5 years	46	44
	<b>Total HSDA:</b>	<b>140</b>	<b>110</b>
VANCOUVER	10 years or more	2117	1517
	5 years or more	1029	840
	<5 years	1182	1002
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4328</b>	<b>3359</b>
<b>Total HA:</b>	<b>4757</b>	<b>3717</b>	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2341	1695
	5 years or more	1106	903
	<5 years	1310	1119
	Never on ART	0	0
<b>Total HA:</b>		<b>4757</b>	<b>3717</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	136	351	54	85
RICHMOND	41	258	15	95
VANCOUVER	506	9376	212	5112
<b>Total:</b>	<b>683</b>	<b>9985</b>	<b>281</b>	<b>5292</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	4
RICHMOND	3
VANCOUVER	97
<b>Total:</b>	<b>104</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	15	16	12
	35-49	76	92	65
	50+	140	228	115
	<b>Total HSDA:</b>		<b>233</b>	<b>338</b>
NORTH VANCOUVER ISLAND	0-19	1	1	0
	20-34	10	11	5
	35-49	35	40	30
	50+	52	79	42
	<b>Total HSDA:</b>		<b>98</b>	<b>131</b>
SOUTH VANCOUVER ISLAND	0-19	9	9	1
	20-34	43	45	32
	35-49	215	258	169
	50+	354	549	277
	<b>Total HSDA:</b>		<b>621</b>	<b>861</b>
<b>Total HA:</b>		<b>952</b>	<b>1330</b>	<b>749</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	2
	20-34	68	72	49
	35-49	326	390	264
	50+	546	856	434
<b>Total HA:</b>		<b>952</b>	<b>1330</b>	<b>749</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	770	1079	609
Female	182	251	140

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	749	51	450	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	105	84
	5 years or more	68	58
	<5 years	60	51
	<b>Total HSDA:</b>	<b>233</b>	<b>193</b>
NORTH VANCOUVER ISLAND	10 years or more	47	37
	5 years or more	22	19
	<5 years	29	21
	<b>Total HSDA:</b>	<b>98</b>	<b>77</b>
SOUTH VANCOUVER ISLAND	10 years or more	305	209
	5 years or more	144	116
	<5 years	172	154
	<b>Total HSDA:</b>	<b>621</b>	<b>479</b>
<b>Total HA:</b>		<b>952</b>	<b>749</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	457	330
	5 years or more	234	193
	<5 years	261	226
<b>Total HA:</b>		<b>952</b>	<b>749</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	161	496	82	162
NORTH VANCOUVER ISLAND	106	221	47	66
SOUTH VANCOUVER ISLAND	177	1451	50	504
<b>Total:</b>	<b>444</b>	<b>2168</b>	<b>179</b>	<b>732</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	41
NORTH VANCOUVER ISLAND	26
SOUTH VANCOUVER ISLAND	78
<b>Total:</b>	<b>145</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	5	6	3
	35-49	14	17	5
	50+	13	17	9
	<b>Total HSDA:</b>		<b>33</b>	<b>41</b>
NORTH WEST	0-19	2	2	0
	20-34	7	11	6
	35-49	24	35	23
	50+	30	43	22
	<b>Total HSDA:</b>		<b>63</b>	<b>91</b>
NORTHERN INTERIOR	0-19	1	1	0
	20-34	30	33	25
	35-49	66	80	57
	50+	71	114	56
	<b>Total HSDA:</b>		<b>168</b>	<b>228</b>
<b>Total HA:</b>		<b>264</b>	<b>360</b>	<b>206</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	4	4	0
	20-34	42	50	34
	35-49	104	132	85
	50+	114	174	87
<b>Total HA:</b>		<b>264</b>	<b>360</b>	<b>206</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	162	226	122
Female	102	134	84

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	206	47	470	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	11	6
	5 years or more	9	4
	<5 years	13	7
	<b>Total HSDA:</b>	<b>33</b>	<b>17</b>
NORTH WEST	10 years or more	16	7
	5 years or more	20	18
	<5 years	27	26
	<b>Total HSDA:</b>	<b>63</b>	<b>51</b>
NORTHERN INTERIOR	10 years or more	48	32
	5 years or more	45	41
	<5 years	75	65
	<b>Total HSDA:</b>	<b>168</b>	<b>138</b>
<b>Total HA:</b>		<b>264</b>	<b>206</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	75	45
	5 years or more	74	63
	<5 years	115	98
<b>Total HA:</b>		<b>264</b>	<b>206</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	27	54	5	8
NORTH WEST	58	135	21	29
NORTHERN INTERIOR	92	353	24	173
<b>Total:</b>	<b>177</b>	<b>542</b>	<b>50</b>	<b>210</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	22
NORTHERN INTERIOR	19
<b>Total:</b>	<b>48</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender**

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	9	6
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	16	28	10
	THOMPSON/CARIBOO/SHUSWAP	21	35	15
	<b>Total HA:</b>	<b>46</b>	<b>78</b>	<b>34</b>
FRASER	FRASER EAST	32	39	25
	FRASER NORTH	63	90	46
	FRASER SOUTH	63	89	50
	<b>Total HA:</b>	<b>158</b>	<b>218</b>	<b>121</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	23	42	20
	RICHMOND	9	14	7
	VANCOUVER	478	742	409
	<b>Total HA:</b>	<b>510</b>	<b>798</b>	<b>436</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	41	65	35
	NORTH VANCOUVER ISLAND	11	20	11
	SOUTH VANCOUVER ISLAND	32	66	25
	<b>Total HA:</b>	<b>84</b>	<b>151</b>	<b>71</b>
NORTHERN	NORTH EAST	6	8	4
	NORTH WEST	29	50	26
	NORTHERN INTERIOR	59	86	55
	<b>Total HA:</b>	<b>94</b>	<b>144</b>	<b>85</b>
<b>Total:</b>		<b>892</b>	<b>1389</b>	<b>747</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	563	896	461
Female	329	493	286

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	747	48	450	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** Persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Combination Therapy:** using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Complera (CPL):** the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.





**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

**Efavirenz (Sustiva, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

**Emtricitabine (FTC):** a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**Famciclovir (Famvir):** a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





**Maraviroc (MVC, Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** The net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.







**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

**Tenofovir (Viread, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Trizivir (TRZ):** ViiV Healthcare's trade name for a pill that combines ABACAVIR (ABC), ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Truvada (TRU):** the Gilead trade name for a pill that contains both TENOFOVIR and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

